OXOLIFE

OXOLIFE

Enhancing embryo implantation. Improving women’s fertility

Founded 2013 Spain

Spain 11 employees Grant Total: $2.50M Biotechnology, Health Care

OXOLIFE is a small-size clinical-stage company founded in 2013, headquartered in Spain, with a focus on female fertility. The company's slogan, "Enhancing embryo implantation. Improving women’s fertility," encapsulates its core mission. OXOLIFE is currently developing an innovative treatment, OXO-001, aimed at enhancing female fertility success and improving embryo implantation through a direct effect on the endometrium. Additionally, the company is conducting research to address PCOS-related infertility. Notably, OXO-001 is a first-in-class drug with a unique mechanism of action, addressing an unmet medical need in the embryo implantation segment. The latest investment of €2.40M Grant was secured on 13 December 2022 from the Ministry of Science and Innovation of Spain. This funding is crucial as it supports the advancement of OXOLIFE's development and clinical trials. The company's leadership, including Agnès Arbat, Medical Doctor (Co-founder and CEO), and Ignasi Canals, Biochemist PhD (Co-founder and CSO), brings extensive experience in the Women’s health pharmaceutical industry and drug development. OXOLIFE also benefits from continuous support from Clinical and Scientific Opinion Leaders from prestigious fertility and R&D centers. As OXOLIFE progresses through its phase II clinical trial with promising primary results, anticipated to be completed by the end of 2023, the company is poised to enter the final stages of clinical development. With its innovative approach and dedicated team, OXOLIFE is well-positioned to address critical challenges in women's health and fertility, offering potential opportunities for impactful advancements in the biotechnology and healthcare industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	€2.40M	1	Ministry of Science and Innovation of Spain	13 Dec 2022
Venture Round	€100.00K	1	BStartup	28 Jan 2021
Grant	Undisclosed	1	EIT Health	02 Jun 2020

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

€2.40M

Ministry of Science and Innovation of Spain

13 Dec 2022

Venture Round

€100.00K

BStartup

28 Jan 2021

Grant

Undisclosed

EIT Health

02 Jun 2020

FAQ About OXOLIFE

Enhancing embryo implantation. Improving women’s fertility

OXOLIFE was founded in 2013.

OXOLIFE is headquartered in Spain.

OXOLIFE operates in Biotechnology and Health Care. Its work centres on female fertility, embryo implantation, PCOS-related infertility and clinical-stage.

OXOLIFE has approximately 11 employees.

OXOLIFE has completed 3 funding rounds, raising a total of $2.50M. The latest funding stage is Grant.

Top alternatives and competitors to OXOLIFE include Novum Pharmaceutical Research Services, Wize Pharma , MacuCLEAR, Gossamer Bio, Applied Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

OXOLIFE and Novum Pharmaceutical Research Services are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About OXOLIFE

Funding Rounds & Investors (3)

Latest News

OXOLIFE Alternatives & Competitors

FAQ About OXOLIFE